Korean biotech ex-Alteogen Loading...

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
00:24
Jan 23
Lee Ju-hyeon Director, Xangle 815 Money Talk (815머니톡)
Prefer other biotech over Alteogen.
The problem is Alteogen-specific, not all biotech; investors should prefer other Korean biotech names with technology-export/licensing expectations rather than buying Alteogen's weak rebound.
Korean biotech ex-Alteogen
MED

About Korean biotech ex-Alteogen Investor Commentary

Across the available history and selected sources, Buzzberg tracks Korean biotech ex-Alteogen across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Lee Ju-hyeon.